Company intelligence
Caidya
Adapting at the Speed of Science.
About Caidya
Caidya is a multi-therapeutic clinical research organization (CRO) serving innovators worldwide. Focused on delivery excellence and an elevated customer experience, Caidya offers a wide range of clinical services and vast therapeutic expertise, supporting its partners from pre-IND strategy, through clinical development to submission and post-marketing surveillance. Caidya leverages industry-leading and proprietary clinical technology to ensure trial transparency and data-driven decision-making. Formed in 2021 following the combination of leading CROs, dMed and Clinipace, Caidya has nearly 1,800 employees in more than 30 countries throughout the world.
Verified activity
Signals from Caidya
5 published signals
Presence & Recognition
Caidya CEO Barbara Lopez Kunz explored the opportunities and complexities of integrating APAC into global clinical development programs in an interview with BioSpectrum Asia.
Reported by Caidya
Research & Knowledge
Caidya published its August 2026 Caidya Monthly Global Regulatory Updates, highlighting global regulatory developments shaping the clinical trials landscape.
Reported by Caidya
Presence & Recognition
Caidya participated in the Medidata NEXT Shanghai 2026 event, where they showcased their clinical research and clinical development expertise.
Reported by Caidya
Partnerships
Caidya partnered with a U.S.-based biotech to support the development of T-cell engagers in autoimmune disease, spanning IIT and IND studies.
Reported by Caidya
Presence & Recognition
Caidya is hosting an exciting lineup of conferences, expert discussions, and opportunities to connect with leaders shaping the future of clinical development in September.
Reported by Caidya